IDEAYA Biosciences Announces Incentive Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCOCalifornia , June 28, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapies, today announced that, June 27, 2024The Compensation Committee of the Board of Directors of IDEAYA has granted non-qualified stock options to purchase an aggregate of 92,000 shares of the Company’s common stock to two newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Incentive Plan (2023 Incentive Plan) as a material inducement for the employment of these individuals by IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Incentive Plan is used exclusively for granting stock awards to individuals who were not previously employees of IDEAYA, or following an actual period of non-employment, as an incentive upon the employment of such individuals at IDEAYA, in accordance with Nasdaq Listing Rule 5635(c)(4).

Stock options have a strike price of $34.37 per share, which is equal to the closing price of IDEAYA common stock on the Nasdaq Global Select Market on the grant date. The stock options have a term of 10 years and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting start date and the remaining 75% of the options vesting in monthly installments. equal over the next three years. . Vesting of stock options is subject to such employee’s continued service with IDEAYA on each vesting date.

__________________

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company engaged in the discovery and development of targeted treatments for selected patient populations using molecular diagnostics. IDEAYA’s approach integrates translational biomarker identification and validation capabilities with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA applies its premier research and drug discovery capabilities to synthetic lethality, which represents an emerging class of targets in precision medicine.

__________________

Investor and media contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
[email protected]

View original content to download multimedia: https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-incentive-grants-under-nasdaq-listing-rule-5635c4-302185134.html

IDEA SOURCEYA Biosciences, Inc.